RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
NCT07009860 on ClinicalTrials.gov · last registry update 2026-08-17
Closed to new participants; the 121 already enrolled are still being followed. Due to report 30 September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Relative (%) reduction in liver stiffness by VCTE compared to baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. pemvidutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P2
- Drug
- pemvidutide
- Sponsor
- Altimmune, Inc.
- Sponsor type
- Industry
- Enrollment
- 121
- Started
- 2025-06-16
- Primary completion
- 2027-09-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Relative (%) reduction in liver stiffness by VCTE compared to baseline
Conditions studied
Alcohol-associated Liver Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the pemvidutide page for this molecule’s full trial and approval history.